CAREDX, INC. Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent
CAREDX, INC. (CDNA) had Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent of $0 as of 2014-12-31, per its 10-K filed 2015-03-31.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent · last filed 2015-03-31
- 2014-12-31: Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent $0.00.
- 2014-09-30: Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent $0.00.
- 2014-06-30: Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent $808.00K.
- 2013-12-31: Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent $525.00K.
| Period end | Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent |
|---|---|
| 2014-12-31 | $0.00 10-K · filed 2015-03-31 |
| 2014-09-30 | $0.00 10-Q · filed 2014-11-14 |
| 2014-06-30 | $808.00K 10-Q · filed 2014-08-28 |
| 2013-12-31 | $525.00K 10-K · filed 2015-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |